Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
Jandu, Haatisha × Aluzaite, Kristina Fogh, Louise Thrane, Sebastian Wingaard Noer, Julie B Proszek, Joanna Do, Khoa Nguyen Hansen, Stine Ninel Damsgaard, Britt Nielsen, Signe Lykke Stougaard, Magnus Knudsen, Birgitta R Moreira, José Hamerlik, Petra Gajjar, Madhavsai Smid, Marcel Martens, John Foekens, John Pommier, Yves Brünner, Nils Schrohl, Anne-Sofie Stenvang, Jan #
BMC Cancer vol:16 issue:1 pages:34
Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects without obtaining any benefit. The aim of this study was to lay the groundwork for development of predictive biomarkers for irinotecan treatment in BC.